|Day Low/High||4.70 / 5.79|
|52 Wk Low/High||1.62 / 4.58|
Nymox Pharmaceuticals (NYMX) is working to get its fexapotide drug approved and may partner with a larger company to help market the medication.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox...
Study Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%
Insiders at these companies have been scooping up shares of their own companies lately.
These under-$10 biotech stocks are within range of triggering breakout trades.
Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.
Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.
Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.
Significantly Better Clinical Outcomes After Up to 2.8 Years for NX-1207 Prostate Cancer Treated Patients Compared to Control Group